Format

Send to

Choose Destination
Expert Rev Vaccines. 2018 Dec;17(12):1105-1110. doi: 10.1080/14760584.2018.1546582. Epub 2018 Nov 15.

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Author information

1
a Division of Infectious Diseases , University Hospitals of Geneva , Geneva , Switzerland.
2
b Centre for Vaccinology , University Hospitals and University of Geneva , Geneva , Switzerland.

Abstract

INTRODUCTION:

The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.

AREAS COVERED:

We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence.

EXPERT COMMENTARY:

Persistence of EBOV-GP-specific antibody responses is strong at 2 years - currently the longest post-vaccination interval studied - after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.

KEYWORDS:

Ebola vaccine; Ebola virus disease; durability; immune response; persistence; rVSV-ZEBOV vaccine; seropositivity

PMID:
30422031
DOI:
10.1080/14760584.2018.1546582
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center